NEW YORK, March 31, 2017 -- Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of the American Depositary Shares of Desarrolladora Homex, S.A.B. de C.V. a/k/a Homex Development Corp. (OTC:DHHXF) (formerly (NYSE:HXM); formerly (OTCMKTS:DHOXQ); formerly (OTCMKTS:DHOXY)) from April 30, 2012 through May 5, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Homex investors under the federal securities laws.
To join the Homex class action, go to http://www.rosenlegal.com/cases-1076.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) between 2010 and 2013, Homex overstated its revenue by 355% or roughly $3.3 billion by reporting fictitious sales of more than 100,000 homes; (2) between 2010 and 2013, Homex overstated the number of units it sold by over 100,000 units or 317% of actual units sold; (3) Homex and certain of its Headquarters Financial Reporting Personnel knowingly and intentionally engaged in a scheme to materially overstate Homex’s revenues, homes sold, and other related financial items; and (4) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 15, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1076.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 



